Compare Inovio Pharmaceuticals Inc (INO) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Petróleo Brasileiro SA — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Petróleo Brasileiro SA trades at $18.29 (market cap $108.78B). The key difference: Petróleo Brasileiro SA is far larger — about 1218.6× Inovio Pharmaceuticals Inc's market cap, and Petróleo Brasileiro SA pays a 9.81% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | PBR | |
|---|---|---|
Market Cap | $89.27M | $108.78B |
Sector | Health | Technology |
52-Week High | $2.87 | $22.03 |
52-Week Low | $1.05 | $11.54 |
Enterprise Value | $60.28M | $171.32B |
Dividend Yield | — | 9.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Petrobras (PBR) trades at $18.19, up 1.22% with bullish technical indicators and strong fundamentals. The stock shows robust profitability with 21.47% net margins and attractive valuation at 5.73 P/E. Recent earnings beat expectations in Q3 and Q4 2025, though Q1 2026 missed estimates. The company maintains strong cash flow generation of $197.5B operating cash flow in 2025 and recently announced strategic acquisitions and renewable energy investments.
PBR presents compelling value with deep discount valuation and 50% analyst buy ratings. Key opportunities include production growth initiatives and dividend sustainability, while risks involve commodity price volatility and geopolitical factors in Latin American operations. The stock's current technical strength combined with fundamental undervaluation supports a positive medium-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
